Arteryex Acquisition To Enhance Eisai's Digital Strategy
Tokyo Venture Adds To Digital Service Platform
Eisai is acquiring Japanese software company Arteryex as part of a digital shift strategy, with the two companies to work together to develop and provide services around personal data, including health records.
You may also be interested in...
Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.
The data collected from wearable devices for a year will provide lifecycle data to a much long-termed study with various health data. The study will not only contribute to drug discovery and personalized healthcare by the firms in near future, but also suggests bigger goals by Japan’s healthcare industry.
Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.